Vinva Investment Management Ltd

Position in EXEL — Exelixis, Inc.

CIK 1968109 SYDNEY, C3

Position in EXEL

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$1,692,259

-$418,100 QoQ

Shares Held

31,102

-36.8% QoQ

Ownership

0.013%

of shares outstanding

% of Portfolio

0.01%

of 13F equity value

Holder Rank

#281

of 756 holders

Holding Since

Dec 2023

11 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

Vinva Investment Management Ltd holds $143,806,233 across 13 Biotechnology names. EXEL ranks #6 (1.2% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	INCY	Incyte Corp	462,843	$52,467,882
2	ALNY	Alnylam Pharmaceuticals, Inc.	154,972	$46,651,221
3	REGN	Regeneron Pharmaceuticals, Inc.	34,494	$21,508,388
4	VRTX	Vertex Pharmaceuticals Inc / Ma	30,687	$15,243,153
5	HALO	Halozyme Therapeutics, Inc.	24,835	$1,943,835
6	EXEL	Exelixis, Inc. This page	31,102	$1,692,259
7	ASND	Ascendis Pharma A/S	4,536	$1,209,841
8	BMRN	Biomarin Pharmaceutical Inc	19,569	$1,119,738

11 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$1,692,259	31,102	-36.8%	Shares	Sole	2026-08-14
2026-03-31	$2,110,359	49,204	+92.0%	Shares	Sole	2026-05-14
2025-12-31	$1,123,494	25,633	+11.6%	Shares	Sole	2026-02-17
2025-09-30	$948,413	22,964	+57.6%	Shares	Sole	2025-11-13
2025-06-30	$642,333	14,572	-29.1%	Shares	Sole	2025-08-13
2025-03-31	$759,001	20,558	-2.3%	Shares	Sole	2025-05-14
2024-12-31	$700,998	21,051	-10.8%	Shares	Sole	2025-02-11
2024-09-30	$612,082	23,587	-2.1%	Shares	Sole	2024-11-14
2024-06-30	$541,145	24,083	+12.1%	Shares	Sole	2024-08-13
2024-03-31	$509,696	21,479	+222.4%	Shares	Sole	2024-05-13
2023-12-31	$159,821	6,662	—	Shares	Sole	2024-02-13
No filing history on record for this holder in this stock.